Antibody-drug conjugates (ADCs) feature specificity and potent chemotherapy. Since their breakthrough in treating solid tumors in 2019, ADCs have become a hot spot for strategic alliances and acquisitions among pharmaceutical companies. In Taiwan, institutes like NHRI, ITRI, DCB, and companies like Mycenax/KRISAN BIOTECH, EirGenix/Formosa Pharmaceuticals, Formosa Laboratories, OBI Pharma, Immunwork, HoneyBear Biosciences, and Topmunnity are pioneering ADC drug development. What groundbreaking innovations and business models propel them into the ADC drug race?
Stay tuned with #Globalbio for the latest updates.
 
Read more: https://news.gbimonthly.com/tw/magazine/article_show.php?num=60174
 
#ADCs #MedicalInnovation #TaiwanBiotech #Healthcare